These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 31019989)
1. Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. Dominov JA; Uyan Ö; McKenna-Yasek D; Nallamilli BRR; Kergourlay V; Bartoli M; Levy N; Hudson J; Evangelista T; Lochmuller H; Krahn M; Rufibach L; Hegde M; Brown RH Ann Clin Transl Neurol; 2019 Apr; 6(4):642-654. PubMed ID: 31019989 [TBL] [Abstract][Full Text] [Related]
2. Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells. Verwey N; Gazzoli I; Krause S; Mamchaoui K; Mouly V; Aartsma-Rus A Nucleic Acid Ther; 2020 Apr; 30(2):71-79. PubMed ID: 31873062 [TBL] [Abstract][Full Text] [Related]
3. In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs. Blázquez L; Aiastui A; Goicoechea M; Martins de Araujo M; Avril A; Beley C; García L; Valcárcel J; Fortes P; López de Munain A Hum Mutat; 2013 Oct; 34(10):1387-95. PubMed ID: 23864287 [TBL] [Abstract][Full Text] [Related]
4. Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Cacciottolo M; Numitone G; Aurino S; Caserta IR; Fanin M; Politano L; Minetti C; Ricci E; Piluso G; Angelini C; Nigro V Eur J Hum Genet; 2011 Sep; 19(9):974-80. PubMed ID: 21522182 [TBL] [Abstract][Full Text] [Related]
5. A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. Dominov JA; Uyan O; Sapp PC; McKenna-Yasek D; Nallamilli BR; Hegde M; Brown RH Ann Clin Transl Neurol; 2014 Sep; 1(9):703-20. PubMed ID: 25493284 [TBL] [Abstract][Full Text] [Related]
6. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion. Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536 [TBL] [Abstract][Full Text] [Related]
7. Full-length dysferlin expression driven by engineered human dystrophic blood derived CD133+ stem cells. Meregalli M; Navarro C; Sitzia C; Farini A; Montani E; Wein N; Razini P; Beley C; Cassinelli L; Parolini D; Belicchi M; Parazzoli D; Garcia L; Torrente Y FEBS J; 2013 Dec; 280(23):6045-60. PubMed ID: 24028392 [TBL] [Abstract][Full Text] [Related]
8. Morpholino-Mediated Exons 28-29 Skipping of Dysferlin and Characterization of Multiexon-skipped Dysferlin using RT-PCR, Immunoblotting, and Membrane Wounding Assay. Anwar S; Yokota T Methods Mol Biol; 2023; 2587():183-196. PubMed ID: 36401031 [TBL] [Abstract][Full Text] [Related]
9. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy. Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335 [TBL] [Abstract][Full Text] [Related]
11. Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities. Poudel BH; Fletcher S; Wilton SD; Aung-Htut M Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891760 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic exon skipping for dysferlinopathies? Aartsma-Rus A; Singh KH; Fokkema IF; Ginjaar IB; van Ommen GJ; den Dunnen JT; van der Maarel SM Eur J Hum Genet; 2010 Aug; 18(8):889-94. PubMed ID: 20145676 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genotypic analysis of a patient with Miyoshi myopathy caused by truncated protein. Zhou J; Zhou R; Feng Q; Song X; Chen X Gene; 2024 Jan; 893():147929. PubMed ID: 38381504 [TBL] [Abstract][Full Text] [Related]
14. An in-frame pseudoexon activation caused by a novel deep-intronic variant in the dysferlin gene. Sun C; Xie Z; Cong L; Xu Y; Liu Z Ann Clin Transl Neurol; 2023 Feb; 10(2):292-296. PubMed ID: 36542547 [TBL] [Abstract][Full Text] [Related]
16. New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Touznik A; Lee JJ; Yokota T Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745 [TBL] [Abstract][Full Text] [Related]
17. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Wein N; Avril A; Bartoli M; Beley C; Chaouch S; Laforêt P; Behin A; Butler-Browne G; Mouly V; Krahn M; Garcia L; Lévy N Hum Mutat; 2010 Feb; 31(2):136-42. PubMed ID: 19953532 [TBL] [Abstract][Full Text] [Related]
18. Novel, de novo dysferlin gene mutations in a patient with Miyoshi myopathy. Hu YY; Lian YJ; Xu HL; Zheng YK; Li CF; Zhang JW; Yan SP Neurosci Lett; 2018 Jan; 664():107-109. PubMed ID: 29138090 [TBL] [Abstract][Full Text] [Related]
19. Compound heterozygous DYSF variants causing limb-girdle muscular dystrophy type 2B in a Chinese family. Li L; Jing Z; Cheng L; Liu W; Wang H; Xu Y; Zheng X; Yu X; Liu S J Gene Med; 2020 Nov; 22(11):e3272. PubMed ID: 32889728 [TBL] [Abstract][Full Text] [Related]
20. Clinical heterogeneity and a high proportion of novel mutations in a Chinese cohort of patients with dysferlinopathy. Xi J; Blandin G; Lu J; Luo S; Zhu W; Béroud C; Pécheux C; Labelle V; Lévy N; Urtizberea JA; Zhao C; Krahn M Neurol India; 2014; 62(6):635-9. PubMed ID: 25591676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]